A digital therapeutic (DTx) developed to help people suffering from insomnia has been shown to improve sleep and mental health in people recovering from a stroke in a clinical trial.
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and
A new treatment for adults with insomnia disorder has been recommended for use in Europe, giving hope to people whose lives are blighted by the condition.
Swiss biotech Idorsia has claimed FDA approval for its first product – insomnia treatment Quviviq – setting up a market challenge to class rivals from Merck & Co and Eisai.
Big Health's Sleepio app for insomnia has been cautiously backed by NICE in preliminary guidance, although the cost-effectiveness agency says more data on longer-term use is needed.
UK-based Big Health has passed a digital health milestone after Scotland became the first country to make anxiety and insomnia digital therapeutics available on a national basis.